Table 1 |
|
|
Baseline characteristics of patients aged ≥ 65 years (n = 108) |
|
|
Category |
n or mean ± SD |
|
|
|
|
Gender (Male/Female) |
54/54 |
|
|
|
|
Age |
68.2 ± 2.8 |
|
|
|
|
Body Weight (kg) |
58.4 ± 9.5 |
|
|
|
|
Body mass index (kg/m2) |
23.3 ± 3.0 |
|
|
|
|
History of interferon therapy (yes/no) |
40/68 |
|
|
|
|
History of diabetes mellitus (yes/no) |
19/89 |
|
|
|
|
History of hypertension (yes/no) |
47/61 |
|
|
|
|
White blood cells (/mm3) |
4909 ± 1332 |
|
|
|
|
Red blood cells (× 104/mm3) |
436.1 ± 39.8 |
|
|
|
|
Hemoglobin (g/dL) |
13.8 ± 1.2 |
|
|
|
|
Platelets (× 104/mm3) |
15.3 ± 3.9 |
|
|
|
|
AST (IU/L) |
65.2 ± 37.3 |
|
|
|
|
ALT (IU/L) |
76.0 ± 65.5 |
|
|
|
|
AFP (ng/ml) |
15.7 ± 31.4 |
|
|
|
|
Histology (METAVIR) Fibrosis (1/2/3/4) |
22/41/37/8 |
|
|
|
|
Histology (METAVIR) Activity (1/2/3) |
30/51/27 |
|
|
|
|
HCV genotype (1/2) |
86/22 |
|
|
|
|
Serum HCV RNA (KIU/ml) |
1650 ± 1521 |
|
|
|
|
Peg-IFN dose (g/kg/week) |
1.22 ± 0.32 |
|
|
|
|
Total Peg-IFN dose > 80% (yes/no) |
63/45 |
|
|
|
|
Daily ribavirin dose (mg/kg) |
9.58 ± 2.93 |
|
|
|
|
Total ribavirin dose > 80% (yes/no) |
63/45 |
|
|
|
|
Data are shown as absolute values or mean ± standard deviation. AST aspartate aminotransferase; ALT alanine aminotransferase; AFP alpha-fetoprotein; HCV hepatitis C virus; Peg-IFN pegylated interferon |
|
|
Nishikawa et al. BMC Research Notes 2012 5:135 doi:10.1186/1756-0500-5-135 |
|
